Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 18/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.58 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.56 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4698408 | 0.86 | OPRM1 (0.74) | OPRM1KCNH2OPRD1OPRK1 | |
| SCHEMBL5755436 | 0.80 | OPRM1 (0.78) | OPRM1KCNH2OPRD1OPRK1 | |
| SCHEMBL4703507 | 0.78 | OPRM1 (0.63) | OPRM1KCNH2OPRD1OPRK1 | |
| Acetic Acid SCHEMBL5754734 | 0.76 | OPRM1 (0.72) | OPRM1KCNH2OPRD1OPRK1 | |
| SCHEMBL7070109 | 0.75 | KCNH2 (0.60) | OPRM1KCNH2OPRD1OPRK1 | |
| SCHEMBL7074406 | 0.74 | OPRM1 (0.67) | OPRM1KCNH2OPRD1OPRK1 | |
| SCHEMBL5755126 | 0.74 | OPRM1 (0.71) | OPRM1KCNH2OPRD1OPRK1 | |
| SCHEMBL5755550 | 0.74 | OPRM1 (0.78) | OPRM1KCNH2OPRD1OPRK1 | |
| SCHEMBL5608182 | 0.74 | KCNH2 (1.00) | OPRM1KCNH2OPRD1OPRK1 | |
| SCHEMBL4699034 | 0.74 | OPRM1 (0.57) | OPRM1KCNH2OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030207876-A1 | 3-Azabicyclo[3.1.0]hexane derivatives useful in therapy | PFIZER, INC. | 2003-11-06 | — | — | US | disclosed |
| US-20020025948-A1 | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy | PFIZER INC. | 2002-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207876-A1 | 3-Azabicyclo[3.1.0]hexane derivatives useful in therapy | OPRD1, OPRK1, OPRM1 | OPRM1 3/4885KCNH2 1279/4885OPRD1 1/4885 |
| US-20020025948-A1 | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy | OPRD1, OPRK1, OPRM1 | OPRM1 3/4885KCNH2 1279/4885OPRD1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.